AFP and cancer: Analysis of the cirrhotic cohort (n = 1,536) showed that the significantly lower overall and cancer-specific mortality risks of the AFP group relative to the AFP+US group were maintained, with adjusted HRs of 0.67 (0.51–0.87; P = 0.003) and 0.59 (0.43–0.82; P = 0.002), respectively, after adjustment of BCLC stage and curative treatment options (S4 Fig and S5 Table).